The Preventive and Interventional Mechanisms of Omega-3 Polyunsaturated Fatty Acids in Krill Oil for Metabolic Diseases

This study explores the preventive and interventional effects of omega-3 polyunsaturated fatty acids (PUFAs) in krill oil on metabolic diseases. Given the rising prevalence of conditions such as type 2 diabetes, hypertension, and dyslipidemia, understanding effective interventions is crucial. However, identifying reliable therapeutic agents poses significant challenges. To address this, we conducted a 24-month randomized, double-blind, placebo-controlled clinical trial involving 300 participants aged 25-65 years with diagnosed metabolic diseases. Participants were randomized into three groups: a placebo control group, a low-dose krill oil group receiving 500 mg daily, and a high-dose krill oil group receiving 1000 mg daily. Data on blood glucose levels, blood pressure, lipid profiles, and inflammatory markers were collected at baseline and at 6, 12, 18, and 24 months. Our results revealed significant improvements in metabolic parameters among the krill oil groups compared to the control group. The low-dose group demonstrated moderate benefits, whereas the high-dose group showed more pronounced effects. Notable improvements were observed in blood glucose levels, blood pressure, lipid profiles (including LDL, HDL, and LDL/HDL ratio), and inflammatory markers (CRP levels). Statistical analyses, including ANOVA, regression models, and dose-response assessments, confirmed the efficacy of krill oil in modulating these parameters. This study provides robust evidence supporting the preventive and interventional roles of omega-3 PUFAs in krill oil, highlighting its potential as a novel therapeutic strategy for metabolic diseases.